We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
J&J last week began the largest phase 3 trial of a COVID-19 vaccine to date, in which it aims to enroll 60,000 participants across eight countries. Read More
A federal court of appeals has rejected a novel plan that would have brought every community in the U.S. into a class-action suit along with 1,300 cities and counties that are suing opioid makers. Read More
Humanigen has teamed up with Massachusetts-based Thermo Fisher Scientific, which will help manufacture the drug substance for Humanigen’s COVID-19 monoclonal antibody lenzilumab. Read More
In the European Union’s (EU) latest move to secure supplies of a COVID-19 vaccine, the European Commission (EC) has signed a contract with Sanofi and GlaxoSmithKline (GSK) for 300 million doses of their vaccine candidate. Read More
The commission has already signed a contract with AstraZeneca for up to 400 million doses of its vaccine and is in ongoing discussions with other companies for supply deals. Read More
In a letter to Gilead Sciences, almost a dozen state treasurers accused the company of seeking “unreasonable profits” from its antiviral COVID-19 treatment remdesivir, demanding that it lower the price. Read More
Eli Lilly has entered into a global partnership with Amgen to increase supply capacity for Eli Lilly’s neutralizing antibodies as a treatment for COVID-19 patients. Read More